In this episode, Dr. Robert Popovian and Ben Blanc are joined by Kate Hudson, Associate Vice President and Counsel for Government Relations and Public Policy at the Association of American Universities, to dissect the complex issue of march-in rights. They delve into how this regulation negatively influences the partnership between public research and private sector investment, which is crucial for supporting biopharmaceutical innovation from university labs to a patient’s bedside. The episode reveals march-in rights' potential risks and benefits, especially how the policy might impact innovation and patient access to future therapies.

Among the highlights in this episode:

02:25: Researchers found that 75% of all Food and Drug Administration-approved drugs between January 2008 and December 2017 were funded and researched by private companies, with only 19% of the approved drugs having origins in publicly supported research and development, and 6% originating in companies that were spun from publicly supported research programs

03:48: Kate shares her professional journey and current role at the Association of American Universities

06:06: Kate explains the concept of march-in rights under the Bayh-Dole Act, detailing its purpose, application, and implications for intellectual property generated from federally funded research

09:52: Dr. Popovian describes his involvement with University Pharmco and its mission to promote research commercialization, emphasizing the potential impact of march-in rights on such initiatives

12:19: Kate addresses why the debate around march-in rights is crucial from a patient's perspective, particularly concerning the potential chilling effect on innovation and drug development

17:18: Kate provides her perspective on how march-in rights could influence private sector investment, potentially driving it outside the United States, and discusses the international adoption of similar legislative frameworks

19:54: Dr. Popovian shares some final thoughts

Contact Our Hosts

Dr. Robert Popovian, Chief Science Policy Officer at GHLF: rpopovian@ghlf.org

Ben Blanc, Associate Director, Digital Production and Engagement at GHLF: bblanc@ghlf.org

A podcast series produced by Ben Blanc.

We want to hear what you think. Send your comments, or a video or audio clip of yourself, to podcasts@ghlf.org

Listen to all episodes of Healthcare Matters on our website or on your favorite podcast channel.

In this episode, Dr. Robert Popovian and Ben Blanc are joined by Kate Hudson, Associate Vice President and Counsel for Government Relations and Public Policy at the Association of American Universities, to dissect the complex issue of march-in rights. They delve into how this regulation negatively influences the partnership between public research and private sector investment, which is crucial for supporting biopharmaceutical innovation from university labs to a patient’s bedside. The episode reveals march-in rights' potential risks and benefits, especially how the policy might impact innovation and patient access to future therapies.
Among the highlights in this episode:
02:25: Researchers found that 75% of all Food and Drug Administration-approved drugs between January 2008 and December 2017 were funded and researched by private companies, with only 19% of the approved drugs having origins in publicly supported research and development, and 6% originating in companies that were spun from publicly supported research programs
03:48: Kate shares her professional journey and current role at the Association of American Universities
06:06: Kate explains the concept of march-in rights under the Bayh-Dole Act, detailing its purpose, application, and implications for intellectual property generated from federally funded research
09:52: Dr. Popovian describes his involvement with University Pharmco and its mission to promote research commercialization, emphasizing the potential impact of march-in rights on such initiatives
12:19: Kate addresses why the debate around march-in rights is crucial from a patient's perspective, particularly concerning the potential chilling effect on innovation and drug development
17:18: Kate provides her perspective on how march-in rights could influence private sector investment, potentially driving it outside the United States, and discusses the international adoption of similar legislative frameworks
19:54: Dr. Popovian shares some final thoughts
Contact Our Hosts
Dr. Robert Popovian, Chief Science Policy Officer at GHLF: <a href="mailto:rpopovian@ghlf.org">rpopovian@ghlf.org</a>
Ben Blanc, Associate Director, Digital Production and Engagement at GHLF: <a href="mailto:bblanc@ghlf.org">bblanc@ghlf.org</a>
A podcast series produced by Ben Blanc.
We want to hear what you think. Send your comments, or a video or audio clip of yourself, to <a href="mailto:podcasts@ghlf.org">podcasts@ghlf.org</a>
Listen to all episodes of Healthcare Matters on our website or on your favorite podcast channel.

Welcome to Healthcare Matters! In this podcast, we talk about 'matters' in healthcare and why it matters to you! 

Our host Ben Blanc will speak with our talented Chief Science Officer Robert Popovian. And together, we will take on some pretty complex topics and distil them, so everyone can understand what is happening in the world of healthcare. 

The show is brought to you by the Global Healthy Living Foundation. 

www.ghlf.org

Welcome to Healthcare Matters! In this podcast, we talk about 'matters' in healthcare and why it matters to you! 
Our host Ben Blanc will speak with our talented Chief Science Officer Robert Popovian. And together, we will take on some pretty complex topics and distil them, so everyone can understand what is happening in the world of healthcare. 
The show is brought to you by the Global Healthy Living Foundation. 
www.ghlf.org

Healthcare Matters

A podcast that pulls back the curtain to help you make sense of complex healthcare economics and policy issues. Our goal is to help simplify the complexities in healthcare economics and policy issues for you.

The podcast is part of the Global Healthy Living Foundation Podcast Network and hosted by Dr. Robert Popovian, Chief Science Policy Officer at GHLF and Ben Blanc, Associate Director, Digital Production and Engagement at GHLF.

A podcast that pulls back the curtain to help you make sense of complex healthcare economics and policy issues. Our goal is to help simplify the complexities in healthcare economics and policy issues for you.
The podcast is part of the Global Healthy Living Foundation Podcast Network and hosted by Dr. Robert Popovian, Chief Science Policy Officer at GHLF and Ben Blanc, Associate Director, Digital Production and Engagement at GHLF.

Advertisement